EYPT JPM Presentation January 2025 vF (2).pdf

1、J.P.Morgan Healthcare Conference PresentationJanuary 14,2025Jay Duker,M.D.President and CEO2025 EyePoint Pharmaceuticals,Inc.All Rights Reserved.Legal Disclaimers2025 EyePoint Pharmaceuticals,Inc.All Rights Reserved.2Various statements made in this presentation are forward-looking,within the meaning

2、 of the U.S.Private Securities Litigation Reform Act of 1995,and are inherently subject to risks,uncertainties and potentially inaccurate assumptions.All statements that address activities,events or developments that we intend,expect,plan or believe may occur in the future,are forward-looking statem

3、ents,including but not limited to statements regarding:our expectations regarding the timing and clinical development of DURAVYU in Wet AMD and DME,our expectations regarding the enrollment,dosing and data readouts for the LUGANO trial and the LUCIA trial;our optimism that that DURAVYU has the poten

4、tial to change the current treatment paradigm and revolutionize real-world outcomes for patients suffering from serious retinal diseases;our belief that DURAVYU has the potential to maintain a majority of patients with active disease with no supplemental anti-VEGF therapy for six months or longer;an

5、d our expectations regarding the timing and clinical development of our other product candidates,including EYP-2301.Forward-looking statements by their nature address matters that are,to different degrees,uncertain.Uncertainties and risks may cause EyePoints actual results to be materially different

6、 than those expressed in or implied by EyePoints forward-looking statements.For EyePoint,these risks and uncertainties include the timing,progress and results of the companys clinical development activities;uncertainties and delays relating to the design,enrollment,completion,and results of clinical